Elevar Therapeutics, Inc.
Subsidiary of HLB Co., Ltd. (028300)
Assets
(3 total)
3Total Assets
1Approved
2Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
lirafugratinib(Lyrfigtu) | Approved | FGFR2Small molecule | Biliary Tract Cancer Cholangiocarcinoma |
| Phase 3 | VEGFR2Small molecule | Non-Small Cell Lung CancerHepatocellular Carcinoma | |
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung CancerCervical CancerHepatocellular CarcinomaGastric CancerNasopharyngeal Carcinoma |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
July 2027 (1)
September 2027 (1)
Est. primary completion 2027-09 · NCT07359820 · CT.gov ↗
What to watch
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
9 April 2027FDA action dateCamrelizumabPDUFA target action date for rivoceranib + camrelizumab (first-line uHCC)
US, FDA · Source ↗
Recent
5 November 2026Filing acceptedCamrelizumabFDA accepts the resubmitted rivoceranib + camrelizumab applications (first-line uHCC)
US, FDA · Source ↗
US, FDA · Elevar Therapeutics, Inc. · Source ↗
23 September 2026ApprovallirafugratinibFDA approves Lyrfigtu in previously treated FGFR2-altered cholangiocarcinoma
US, FDA · Elevar Therapeutics, Inc. · Source ↗
10 July 2026Complete response letterApatinibFDA issues complete response letter for rivoceranib + camrelizumab NDA (first-line uHCC)
US, FDA · Elevar Therapeutics, Inc. · Source ↗
10 July 2026Complete response letterCamrelizumabFDA issues complete response letter for rivoceranib + camrelizumab (first-line uHCC)
US, FDA · Elevar Therapeutics, Inc. · Source ↗
Financial reports
No financial reports recorded.